Diagnostics company Droplet Biosciences announced on Tuesday that it is partnering with Nvidia to leverage the chipmaker's AI framework for accelerating post-surgery cancer test outcomes.

The firm has been utilizing Nvidia Parabricks, a GPU-accelerated software package, to significantly accelerate genomic data analysis for DNA sequencing.

Droplet claims its approach can identify leftover disease within 24 hours by examining lymphatic fluid gathered after surgery, whereas conventional blood tests usually take four to six weeks for tumor traces to show up.

"Through the acceleration provided by NVIDIA Parabricks, we have managed to reduce several of our most compute-heavy processes from over a day to only a few hours," stated Droplet's chief scientific officer, Wendy Winckler.

Also Read: Republic Day 2026: India's Tech Triumphs & Global Leadership

The firm noted that it experienced operational advantages despite increased hourly expenses for GPU computing, stating, "The significantly shortened runtime leads to a decreased total cost per sample."

Quicker results enable patients to receive their findings while still admitted, eliminating the need for additional visits or extended waits associated with standard blood tests, it noted.

"We utilize Parabricks to accelerate our genomic analysis and reduce turnaround time from 10 days to under five days," stated Zhuosheng Gu, senior director of informatics, R&D at Droplet Biosciences.

The initial clinical trial of the diagnostic startup targets HPV-negative head and neck cancer, approved in accordance with the Clinical Laboratory Improvement Amendments.

Also Read: AI & Tech: Visionary Pre-Budget Insights from Industry Leaders

Droplet Biosciences has altered the timeline and method of detecting residual cancer post-surgery by gathering lymphatic fluid 24 hours following the removal of a patient's tumor. In contrast to blood tests that are commonly utilized for minimal residual disease (MRD) monitoring, lymphatic fluid enables earlier collection and enhances sensitivity.

Also Read: NVIDIA's Rubin Moment at CES: AI Supercomputing Breakthrough

Specifically, the Droplet Biosciences team discovered that lymphatic fluid collected after surgery contains 130 times more tumor-derived DNA molecules than blood plasma taken at the same time. The notable rise in DNA molecules derived from tumors can be linked to their proximity to the tumor site instead of being dispersed in large volumes of blood.